Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RemEP: Post-exposure prophylaxis with remdesivir for Ebola virus disease
jRCTs031220480Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of remdesivir in Ebola virus disease (EVD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of Ebola virus disease. Started Dec 2022; status: completed.
02
Drugs
remdesivir
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on jRCTs031220480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220480.